Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) Operating Income (2022 - 2025)

Historic Operating Income for Indivior Pharmaceuticals (INDV) over the last 4 years, with Q3 2025 value amounting to $43.0 million.

  • Indivior Pharmaceuticals' Operating Income rose 2285.71% to $43.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $227.0 million, marking a year-over-year increase of 44047.62%. This contributed to the annual value of -$23.0 million for FY2024, which is 8486.84% up from last year.
  • Indivior Pharmaceuticals' Operating Income amounted to $43.0 million in Q3 2025, which was up 2285.71% from $72.0 million recorded in Q2 2025.
  • In the past 5 years, Indivior Pharmaceuticals' Operating Income ranged from a high of $72.0 million in Q2 2025 and a low of -$258.0 million during Q4 2022
  • Its 4-year average for Operating Income is $4.6 million, with a median of $56.5 million in 2022.
  • Per our database at Business Quant, Indivior Pharmaceuticals' Operating Income plummeted by 42678.57% in 2023 and then soared by 16101.69% in 2025.
  • Over the past 4 years, Indivior Pharmaceuticals' Operating Income (Quarter) stood at -$258.0 million in 2022, then skyrocketed by 123.26% to $60.0 million in 2023, then dropped by 23.33% to $46.0 million in 2024, then fell by 6.52% to $43.0 million in 2025.
  • Its Operating Income was $43.0 million in Q3 2025, compared to $72.0 million in Q2 2025 and $66.0 million in Q1 2025.